Heart failure & cardiomyopathies
American Registry of Ambulatory and Acute Decompensated Heart Failure (AMERICCAASS Registry): Rationale and Design
Study context
- Population
- Patients with ambulatory or acute decompensated heart failure (HF) in the American continent, hospital-based institutions in the Americasrecruitment ongoing
- Planned comparison
- Ambulatory HF vs Acute decompensated HF
- Primary endpoint
- Rehospitalization and survival
- Follow-up
- 12 months
Methodological detailsrationale and design, observational, hospital-based, multinational, ongoing, Started 1 April 2022; recruitment to end 30 November 2023; follow-up to 31 January 2025, Follow-up at 12 months (ambulatory) or 1, 6 and 12 months after discharge (acute decompensated HF), Readmissions and post-discharge mortality as proportions at 1, 6 and 12 months; Kaplan-Meier survival analysis
- Rationale and design
- Observational
- Hospital-based
- Multinational
- Ongoing
- Started 1 April 2022; recruitment to end 30 November 2023; follow-up to 31 January 2025
- Follow-up at 12 months (ambulatory) or 1, 6 and 12 months after discharge (acute decompensated HF)
- Readmissions and post-discharge mortality as proportions at 1, 6 and 12 months; Kaplan-Meier survival analysis
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
American Registry of Ambulatory and Acute Decompensated Heart Failure (AMERICCAASS Registry): Rationale and Design. ESC Heart Fail. Published 16 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →